Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Naigeon · SciRah

Researcher profile · Semantic Scholar

M. Naigeon

Share profile

M. Naigeon — researcher profile on SciRah

h-index: 15
Works: 50
Citations: 1,120

Most-cited papers

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer
C. Coutzac, J. Jouniaux, A. Paci, J. Schmidt +21 more
2020Nature Communications464 citations Open access
Semantic Scholar
Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
R. Ferrara, M. Naigeon, É. Auclin, B. Duchemann +20 more
2020Clinical Cancer Research141 citations Open access
Semantic Scholar
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics.
L. Mezquita, I. Preeshagul, É. Auclin, D. Saravia +33 more
2021European Journal of Cancer57 citations Open access
Semantic Scholar
Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study
L. Carril-Ajuria, A. Desnoyer, M. Meylan, C. Dalban +19 more
2022Journal for ImmunoTherapy of Cancer50 citations Open access
Semantic Scholar
The use of immunotherapy in older patients with advanced non-small cell lung cancer.
M. Tagliamento, M. Frélaut, C. Baldini, M. Naigeon +3 more
2022Cancer Treatment Reviews46 citations Open access
Semantic Scholar
Immunosenescence, inflammaging, and cancer immunotherapy efficacy
Julieta E. Rodriguez, M. Naigeon, V. Goldschmidt, Matthieu Roulleaux Dugage +10 more
2022Expert Review of Anticancer Therapy45 citations
Semantic Scholar
B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors
R. Flippot, Marcus Teixeira, M. Rey-Cárdenas, L. Carril-Ajuria +11 more
2024Journal for ImmunoTherapy of Cancer44 citations Open access
Semantic Scholar
Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients.
M. Charrier, L. Mezquita, B. Lueza, L. Dupraz +14 more
2019European Journal of Cancer39 citations Open access
Semantic Scholar
CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
B. Duchemann, M. Naigeon, É. Auclin, R. Ferrara +11 more
2022Journal for ImmunoTherapy of Cancer37 citations Open access
Semantic Scholar
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer
B. Duchemann, J. Remon, M. Naigeon, L. Mezquita +9 more
2020Cancers34 citations Open access
Semantic Scholar
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLC
M. Naigeon, Matthieu Roulleaux Dugage, F. Danlos, L. Boselli +18 more
2023Science Advances28 citations Open access
Semantic Scholar
Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer
B. Duchemann, J. Remon, M. Naigeon, L. Cassard +7 more
2020Translational Lung Cancer Research26 citations Open access
Semantic Scholar
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial.
M. Riudavets, M. Naigeon, M. Texier, M. Dorta +12 more
2021Lung Cancer18 citations Open access
Semantic Scholar
Metabolic tumor volume assessed by 18F FDG - PET CT scan as a predictive biomarker for immune checkpoint blockers in advanced NSCLC and its biological correlates.
F. Dall'Olio, W. Zrafi, V. Roelants, V. Ambrosini +47 more
2024Clinical Cancer Research15 citations Open access
Semantic Scholar
The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection
Déborah Lécuyer, R. Nardacci, Désirée Tannous, Emie Gutierrez-Mateyron +27 more
2023bioRxiv15 citations Open access
Semantic Scholar
Adoptive cell therapies in thoracic malignancies
J. Lasvergnas, M. Naigeon, K. Chouahnia, L. Zelek +2 more
2022Cancer Immunology and Immunotherapy11 citations Open access
Semantic Scholar
Blood-based circulating biomarkers for prediction of immune-checkpoint inhibitors efficacy in renal cell carcinoma
Loubna Omri, M. Naigeon, R. Flippot, J. Gavira-Díaz +8 more
2024Exploration of Targeted Anti-tumor Therapy9 citations Open access
Semantic Scholar
Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L)1 inhibitors (IO).
R. Ferrara, M. Naigeon, É. Auclin, B. Duchemann +15 more
2018Annals of Oncology8 citations Open access
Semantic Scholar
Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131 and 150 trials.
É. Auclin, Matthieu Roulleaux Dugage, T. Gorría, C. Vauchier +8 more
2024Lung Cancer7 citations Open access
Semantic Scholar
MA07.01 Circulating Immature Neutrophils, Tumor-Associated Neutrophils and dNLR for Identification of Fast Progressors to Immunotherapy in NSCLC
L. Mezquita, P. Martin-Romano, É. Auclin, B. Duchemann +12 more
2019Journal of Thoracic Oncology7 citations Open access
Semantic Scholar
High circulating IL-6/IL-8 is associated with intratumoral myeloid contexture and poor outcomes in advanced renal cell carcinoma patients treated with PD-1 blockade.
L. Carril-Ajuria, R. Flippot, M. Naigeon, C. Dalban +13 more
2025Clinical Cancer Research6 citations
Semantic Scholar
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
L. Mourey, L. Rainho, C. Dalban, L. Carril-Ajuria +18 more
2024European Journal of Cancer4 citations
Semantic Scholar
Baseline circulating soluble factors as predictors of immune-related adverse events (irAEs) in patients (pts) with metastatic clear cell renal carcinoma (mRCC) treated with nivolumab: A translational NIVOREN GETUG-AFU 26 study.
L. Carril-Ajuria, M. Naigeon, C. Dalban, A. Desnoyer +12 more
2023Journal of Clinical Oncology2 citations Open access
Semantic Scholar
The impact of baseline peripheral cytokines on survival in metastatic clear cell renal cell carcinoma (RCC) treated with nivolumab: NIVOREN GETUG-AFU 26 Translational study.
L. Carril, M. Naigeon, C. Dalban, A. Desnoyer +11 more
2022Journal of Clinical Oncology2 citations
Semantic Scholar
1294P 18F-FDG PET-TC derived parameters as a tool to select pembrolizumab single agent or in combination with chemotherapy in first-line NSCLC
F. Dall'Olio, C. García, A. Bettaieb, M. Naigeon +16 more
2021Annals of Oncology2 citations Open access
Semantic Scholar
Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts).
R. Ferrara, M. Naigeon, É. Auclin, B. Duchemann +14 more
2019Annals of Oncology2 citations Open access
Semantic Scholar
184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study
L. C. Ajuria, M. Naigeon, R. Flippot, C. Dalban +12 more
2023Immuno-Oncology and Technology1 citations Open access
Semantic Scholar
20P Human virome epitope-level antiviral antibody profiling identified the cytomegalovirus (CMV) as the main driver of senescent immune phenotype (SIP) in patients with advanced non-small cell lung cancer (aNSCLC)
M. Naigeon, M. R. Dugage, F. Danlos, C. de Oliveira +9 more
2022Immuno-Oncology and Technology1 citations Open access
Semantic Scholar
687P NIVOREN GETUG-AFU 26 translational study: Baseline peripheral cytokines predict survival in metastatic clear cell renal carcinoma (RCC) treated with nivolumab
L. C. Ajuria, M. Naigeon, C. Dalban, A. Desnoyer +11 more
2021Annals of Oncology1 citations Open access
Semantic Scholar
P1.01-18 Immunosenescence Correlates with Progression upon PD-(L)-1 Blockade (IO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients
R. Ferrara, M. Naigeon, É. Auclin, B. Duchemann +15 more
2018Journal of Thoracic Oncology1 citations Open access
Semantic Scholar
PD1+ TIGIT+ CD4+ T cells predict response to anti-TNF in rheumatoid arthritis and spondyloarthritis
S. Bitoun, M. Roulleaux-Dugage, M. Naigeon, Caroline de Oliveira +4 more
2026RMD Open0 citations Open access
Semantic Scholar
30 Myeloid- Versus Effector-Driven Circulating Immune States Define Treatment-Specific Benefit in Metastatic Clear Cell Renal Cell Carcinoma
M. Calabrese, N. Chaput, Marine Aglave, M. Rey-Cárdenas +9 more
2026The Oncologist0 citations Open access
Semantic Scholar
P3.142: SENLOAD Study: Association of Baseline CD8 T-Cell Senescence With Survival in Unresectable Stage III NSCLC
J. Benítez, M.-V. Sanchez-Becerra, M. Naigeon, W. Zrafi +14 more
2026Journal of Thoracic Oncology0 citations
Semantic Scholar
58 Baseline Peripheral TCR Diversity as a Biomarker of Response to First-line Immunotherapy in Metastatic Clear Cell Renal Cell Carcinoma
Luigi Roca, N. Chaput, M. Calabrese, M. Rey-Cárdenas +10 more
2026The Oncologist0 citations Open access
Semantic Scholar
Future approaches to immune base biomarkers.
M. R. Dugage, F. Danlos, Julien Vibert, C. Pottier +7 more
2026Annals of Oncology0 citations
Semantic Scholar
Circulating angiogenic–myeloid cytokine axis to predict benefit from first-line immune-checkpoint inhibitor combinations in metastatic clear cell renal cell carcinoma.
M. Calabrese, N. Chaput, M. Rey, J. Jouniaux +9 more
2026Journal of Clinical Oncology0 citations Open access
Semantic Scholar
Abstract 6042: Baseline serum level of IgG targeting annexin A2 is predictive of response to immunotherapy in patients with advanced NSCLC
M. R. Dugage, F. Danlos, M. Bonvalet, Tyler Hulett +15 more
2025Cancer Research0 citations
Semantic Scholar
1525P High myeloid clonality rate predicts resistance to immune checkpoint blockers in non-small cell lung cancer
C. Baldini, J. E. Rodríguez, M. R. Dugage, C. Massard +10 more
2025Annals of Oncology0 citations Open access
Semantic Scholar
Expanded senescent CD8 T-cells in IMID patients are associated with distinct inflammatory cytokines.
M. Naigeon, S. Bitoun, Matthieu Roulleaux Dugage, Caroline de Oliveira +7 more
2025Clinical and Experimental Immunology0 citations Open access
Semantic Scholar
15P Plasma proteomics identify signature of CD8+ T cell senescence associated with ICB resistance in aNSCLC patients
M. Naigeon, M. R. Dugage, L. Girard, F. Danlos +6 more
2025Immuno-Oncology and Technology0 citations Open access
Semantic Scholar
P1.08B.02 Circulating T-Cell Immunosenescence in Patients with Unresectable Locally Advanced NSCLC: Preliminary Results of the SENLOAD Study
J. Benítez, M. V. Sanchez-Becerra, N. Chaput, M. Naigeon +14 more
2024Journal of Thoracic Oncology0 citations
Semantic Scholar
POS1322 IMID PATIENTS SHOW EXPANDED SENESCENT CD8 T-CELLS ASSOCIATED WITH LEVELS OF CIRCULATING INTERFERON GAMMA AND IL-6
S. Bitoun, M. Naigeon, M. Roulleaux-Dugagé, C. de Oliveira +4 more
2024Scientific Abstracts0 citations
Semantic Scholar
Circulating Proteins Associated with Anti-IL6 Receptor Therapeutic Resistance in the Sera of Patients with Severe COVID-19.
J. Michot, V. Dozio, J. Rohmer, F. Pommeret +26 more
2024Journal of Proteome Research0 citations
Semantic Scholar
23P Circulating immune cells and activity of immune checkpoint inhibitors in metastatic renal cell carcinoma
R. Flippot, M. Teixeira, E. Roblin, L. C. Ajuria +7 more
2023Immuno-Oncology and Technology0 citations Open access
Semantic Scholar
1909P Baseline cytokine levels according to the line of treatment in patients with metastatic clear cell renal cell carcinoma treated with nivolumab: NIVOREN GETUG-AFU 26 translational study
L. T. Rainho, L. Albiges, R. Flippot, L. C. Ajuria +6 more
2023Annals of Oncology0 citations Open access
Semantic Scholar
11P Senescent immune phenotype (SIP) status that predicts resistance to immune checkpoint blockers (ICB) among CMV+ advanced non-small cell lung cancer (aNSCLC) patients is not associated with chronic type I IFN signature
M. Naigeon, C. de Oliveira, F. Danlos, B. Duchemann +9 more
2021Annals of Oncology0 citations Open access
Semantic Scholar
1286P Senescent immune phenotype (SIP) status predicts resistance to immune checkpoint blockers (ICB) among CMV+ advanced non-small cell lung cancer (aNSCLC) patients
M. Naigeon, C. de Oliveira, F. Danlos, B. Duchemann +10 more
2021Annals of Oncology0 citations Open access
Semantic Scholar
P33.10 Identification of Long-Responders and Fast-Progressors under Immunotherapy Based on Early Monitoring of dNLR in Advanced NSCLC Patients
M. Riudavets, É. Auclin, F. Blanc-Durand, A. De Giglio +13 more
20210 citations Open access
Semantic Scholar
1735P Circulating T-cell immunosenescence in patients with thymic epithelial tumors (TETs)
J. Benítez, M. Naigeon, O. Lambotte, V. D. De Montpreville +13 more
2021Annals of Oncology0 citations Open access
Semantic Scholar
P1.04-31 Immunosenescence Correlates with Poor Outcome from PD-(L)1 Blockade but Not Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
R. Ferrara, M. Naigeon, É. Auclin, B. Duchemann +18 more
2019Journal of Thoracic Oncology0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

B. Besse×29
Invite
B. Besse — researcher profile on SciRah
N. Chaput×24
Invite
N. Chaput — researcher profile on SciRah
L. Cassard×23
Invite
L. Cassard — researcher profile on SciRah
L. Boselli×18
Invite
L. Boselli — researcher profile on SciRah

×16

Invite

D. Planchard — researcher profile on SciRah

B. Duchemann×14

Invite

B. Duchemann — researcher profile on SciRah

Invite

F. Danlos — researcher profile on SciRah

Invite

É. Auclin — researcher profile on SciRah

A. Desnoyer×12

Invite

A. Desnoyer — researcher profile on SciRah

Invite

N. Chaput — researcher profile on SciRah

J. Jouniaux×11

Invite

J. Jouniaux — researcher profile on SciRah

Invite

J. Grivel — researcher profile on SciRah